Imatinib Terminated Phase 3 Trials for Leukemia, Myeloid, Chronic Phase Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00124748Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)